HOME > Our Company > Corporate Profile > History

History

-1950

1912 10 Taisho Seiyakusho was founded.
1927   Cough suppressant "Pabron" was launched.
1928 5 Taisho Pharmaceutical Co., Ltd., was established in Tokyo's Bunkyo Ward.
1929 11 Osaka branch was established.
1943 6 Upon the passing of Taisho president Kinujiro Ishii, Teruji Ishii assumed the post.
  7 Head office moved to Tokyo's Toshima Ward.
1946 6 Managing Director Shokichi Uehara assumed post of president.
1948 5 Company's Japanese name was changed.

1951-1970

1953 6 Dermatologic preparation "Dermarin" was launched.
1955 7 Eagle trademark was adapted.
1957 9 Eye drops "Iris" was launched.
  10 The first ethical drug of our company, "Psorion" was launched.
1960 10 Antipyretic analgesics "Naron" was launched.
1962 3 Energy drink "Lipovitan D" was launched.
1963 1 Omiya Factory was constructed.
  9 Taisho's shares were listed on Second Section of the Tokyo Stock Exchange.
1966 8 Taisho's shares were listed on First Section of the Tokyo Stock Exchange.
1967 8 The Antiphlogistic pain reliever "Opyrin Tablet" was launched.

1971-1990

1973 5 Vice-President Shoji Uehara assumed post of president.
1974 7 Research Center was constructed on premises of Omiya Factory.
1977 5 Head office moved to new offices.
1978 6 The Special Agreement System with Shareholder-Operated stores was implemented.
  8 "Taisho Kanpo Ichoyaku (Herbal Stomach Remedy)" was launched.
1982 6 President Shoji Uehara assumed post of chairman.
  6 Vice-President Akira Uehara assumed post of president.
1983 3 Former chairman Shokichi Uehara passed away.
  9 Joint venture, Sanofi-Taisho Pharmaceuticals Co., Ltd., was established.
  9 Taisho Pharmaceutical (H.K.) Co., Ltd., was established.
  10 Nutrient foods "Biodyna" series was launched.
1984 3 Antiulcer agent "Solon" was launched.
  6 Taisho Pharmaceutical (Taiwan) Co., Ltd., was established.
1985 2 The Uehara Memorial Foundation was established.
  3 Shoji Uehara assumed post of chairman of the Proprietary Association of Japan.
  9 Okayama Factory was constructed.
1988 4 The Support VAN system, which handles sales information collected through POS cash registers, was developed
  10 Taisho Pharmaceutical California Inc. was established.
  10 "Palux injection", Peripheral vasodilator, was launched.
1990 9 Taisho Pharmaceutical (Malaysia) Sdn. Bhd. was established.
  10 Omiya Factory redevelopment planning, the first-phase construction, including Building No. 1 and certain facilities for common use, was completed.

1991-2000

1991 6 Antibiotic "Clarith tablets" were launched.
1992 8 Taisho Pharmaceuticals (Philippines) Inc. was established.
  12 Energy drink "Zena F-II" and "Zena F-III" were launched.
1993 6 The Research Center and new Research Laboratory were completed.
  10 Omiya Factory redevelopment planning, the second-phase construction, including the automated materials warehouse and the public welfare building, was completed.
1995 1 Pt. Taisho Indonesia was established.
1996 3 Osotspa Taisho Co., Ltd was established.
  8 Former chairman Sae Uehara passed away.
1997 7 Hanyu Factory was completed as the third-phase construction.
  8 Shanghai Taisho Guan Sheng Yuan Co., Ltd. was established.
  8 Taisho Hizon Manufacturing, Inc. was established.
1998 7 Taisho Pharmaceutical Logistics Co., Ltd. was established.
1999 4 "Lipovitan D" became available in convenience stores, supermarkets and other outlets.
  6 "RiUP" -Japan's first drug for male-pattern baldness- was launched.
  6 Akira Uehara assumed post of chairman of WSMI.
  7 Omiya Factory redevelopment planning, the fourth-phase construction, including the Investigational Drug Production Center and the New Synthesis Building were completed.
  7 TAISHO VIETNAM Co., Ltd. was established.
2000 3 Uehara Museum of Modern Art was established.
  6 Orthopedic filling paste "Biopex" was launched.
  7 Taisho Beijing Office was established.

2001-

2001 2 NSAID "Lorcam tablets" were launched.
  3 Taisho's Omiya Factory received ISO14001 certification.
  7 Activated vitamin D3 formulation "Hornel tablets" were launched.
  8 TAISHO Pharmaceutical R&D USA Inc. was established.
2002 3 Taisho's Hanyu Factory received ISO 14001 certification.
  5 Omiya Factory redevelopment planning, the fifth-phase construction, was completed.
  5 Taisho took over the "VICKS Medicated Drops" from Procter & Gamble.
  8 Taisho announced a capital and business alliance with Toyama Chemical Co., Ltd.
  10 Second building of Taisho Pharmaceutical's head office was completed.
  10 Taisho Toyama Pharmaceutical Co., Ltd. was established.
2003 2 Food for specified health uses (FOSHU) total brand "Livita" started.
  3 Taisho's Okayama Factory received ISO 14001 certification.
  7 Mejiro Real Estate Co., Ltd. was established.
  10 Taisho and P&G signed sole distributorship contract for "VICKS VapoRub", a rub-type cold remedy.
2004 3 "Lipovitan D" reaches a 20-billion milestone in total shipments.
  3 Taisho Pharmaceutical realized zero waste emission at Hanyu Factory.
2005 3 Taisho Pharmaceutical realized zero waste emission at Omiya Factory.
  3 "RiUP Lady," a hair regrowth treatment, was launched.
  7 "Pabron" and "Taisho Kampo" was launched in Thailand.
  7 Taisho forged business and capital ties with Yomeishu Seizo Co., Ltd.
  8 Yokohama Distribution Center was constructed.
  9 Taisho Active Health Co., Ltd. was established.
2006 3 E-commerce website, Taisho Pharmaceutical Direct Online Shopping was released.
  3 New product "Nourish Biboukassai", skincare brand was launched.
  4 Acquired additional stock in Yomeishu Seizo Co., Ltd., which became equity method affiliate of Taisho.
  5 Taisho Pharmaceutical realized zero waste emission at all domestic factories.
  7 "Pabron" and "Taisho Kampo" were launched in Malaysia.
  9 Taisho to License New-ingredient Anti-inflammatory Analgesic from TOKUHON corporation.
  9 Taisho has entered into an agreement with Chugai Pharmaceutical to co-development and co-marketing for the antiresorptive bisphosphonate.
2007 6 Omiya Factory's Drug Formulation Building No.2 was completed.
  10 "Geninax(R) Tablet", an oral new-type quinolone antibacterial agent, was launched.
  10 Fukuoka branch moved to new office.
2008 3 "hisoca," a Herb concentrated drinks joint development with Isetan was launched.
  3 Acquired shares in Biofermin Pharmaceutical Co., Ltd., which became consolidated subsidiary.
  5 Taisho has entered into an agreement with Chugai Pharmaceutical Co., Ltd. to co-development and co-marketing for the activated vitamin D3 derivative.
  10 "Zosyn(R)" was launched in Japan: an injectable antibiotic combination product consisting of semisynthetic antibiotic and lactamase inhibitor.
  10 The stock transfer based on basic agreement of a strategic capital and business alliance by FUJIFILM Holdings, Taisho Pharmaceutical, and Toyama Chemical was concluded.
2009 6 "RiUP X5," a minoxidil 5% product was launched.
  10 Acquired OTC Drug Trademarks, Etc. and PT Bristol-Myers Squibb Indonesia Tbk Shares held by Bristol-Myers Squibb Company in Asia.
  10 Taisho Pharmaceutical Singapore Private Limited was established.
2010 1 The new quinolone antibacterial agent "OZEX(R)" was launched.
  3 Taisho Pharmaceutical ended the Special Agreement System with Shareholder-Operated stores.
  10 The new quinolone antibacterial product for injections "PASIL(R) Injection" was launched.
2011 4 The osteoporosis agent "Edirol(R) Capsule" was launched.
  8 Acquired shares of Hoepharma Holdings Sdn.Bhd.
  10 Taisho Pharmaceutical Holdings Co., Ltd. was established.
2012 3 "Lipovitan D" marked its 50th anniversary.
  6 Executive Vice-President Shigeru Uehara assumed post of President.
  7 Acquired 100% of the shares of a Mexican pharmaceutical company group.(4 companies including CICSA)
  7 Osaka branch moved to new office.
  10 Taisho Pharmaceutical celebrated its 100th anniversary of foundation.
2013 4 "Epadel T", Japan's first switch-OTC drug for lifestyle-related diseases was launched.
  8 The new agent for osteoporosis "Bonviva(R) IV Injection" was launched.

Page Top